Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Научно-исследовательский институт фармакологии им. В.В.Закусова РАМН, Москва
Список исп. литературыСкрыть список 1. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012;. 32 (2): 153–64. 2. Mastronardi C, Paz-Filho GJ, Valdez E et al. Long-term body weight outcomes of antidepressant-environment interactions. Mol Psychiatry 2011; 16 (3): 265–72. 3. Baicy K, London ED, Monterosso J et al. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci USA 2007; 104 (46): 18276–9. 4. Naqvi N H, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science 2007; 315 (5811): 531–4. 5. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101 (13): 4531–6. 6. Licinio J, O’Kirwan F, Irizarry K et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004; 9 (12): 1075–82. 7. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13 (8): 800–12. 8. Kim S J, Lee H, Joung HY et al. T-bet deficient mice exhibit resistance to stress-induced development of depression-like behaviors. J Neuroimmunol 2011; 240–1: 45–51. 9. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66 (5): 488–97. 10. Dong C, Wong M L, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14 (12): 1105–18. 11. Blalock J E. The immune system as a sensory organ. J Immunol 1984; 132 (3): 1067–70. 12. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25 (4): 767–80. 13. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 20–34. 14. Meyer U, Feldon J, Fatemi S. H. In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev 2009; 33 (7): 1061–79. 15. Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010; 30 (4): 1270–87. 16. Meyer U, Nyffeler M, Yee BK et al. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008; 22 (4): 469–86. 17. Clarke MC, Tanskanen A, Huttunen M et al.. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry 2009; 166 (9): 1025–30. 18. Abazyan B, Nomura J, Kannan G et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry 2010; 68 (12): 1172–81. 19. Vuillermot S, Joodmardi E, Perlmann T et al. Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J Neurosci 2012; 32 (2): 436–51. 20. Newman SC, Bland RC. A population-based family study of DSM-III generalized anxiety disorder. Psychol Med 2006; 36 (9): 1275–81. 21. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158 (10) : 1568–78. 22. Scherrer JF, True WR, Xian H et al. Evidence for genetic influences common and specific to symptoms of generalized anxiety and panic. J Affect Disord 2000; 57 (1–3): 25–35. 23. Le-Niculescu H., Balaraman Y, Patel SD et al. B. Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms. Transl Psychiatry 2011; 1: e9. 24. Amstadter AB, Koenen KC, Ruggiero K J et al. NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depress Anxiety 2010; 27 (3): 270–5. 25. Domschke K, Tidow N, Kuithan H et al. Monoamine oxidase A gene DNA hypomethylation – a risk factor for panic disorder? Int J Neuropsychopharmacol 2012; 15 (9): 1217–28. 26. Nitschke JB, Sarinopoulos I, Oathes DJ et al. H. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009; 166 (3): 302–10. 27. Arce E, Miller DA, Feinstein JS et al. Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology (Berl) 2006; 189: (1): 105–16. 28. Aupperle RL, Ravindran L, Tankersley D et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology 2011; 36 (7): 1466–77. 29. Ball TM, Ramsawh HJ, Campbell-Sills L et al. Prefrontal dysfunction during emotion regulation in generalized anxiety and panic disorders. Psychol Med 2012.10.1017/S0033291712002383): 1–12. 30. Hariri AR, Mattay VS, Tessitore A et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297 (5580): 400–3. 31. Zhou Z, Zhu G, Hariri AR et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008; 452 (7190): 997–1001. 32. Domschke K, Reif A, Weber H et al. Neuropeptide S receptor gene – converging evidence for a role in panic disorder. Mol Psychiatry 2011; 16 (9.): 938–48. 33. Domschke K, Braun M, Ohrmann P et al. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol 2006; 9 (3): 349–55. 34. Lohoff FW, Aquino TD, Narasimhan S et al. Serotonin receptor 2A (HT2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2013; 13 (1): 21–6. 35. Lenze EJ, Goate AM, Nowotny P et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol 2010; 30 (6): 672–7. 36. Perna G, Favaron E, Di Bella D et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005; 30 (12): 2230–5. 37. Baffa A, Hohoff C, Baune BT et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010; 62 (2) 121–31.